Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK
Edited by the Laboratorytalk Editorial
Team on 03 November 2004
Genetic mutations and bowel cancer
Screening for a variety of genes could determine bowel cancer risk, with 20% of cases being due to multiple genetic mutations, according to research from Cancer Research UK
Cancer Research UK scientists at the University of Oxford have found that a number of genetic mutations could collectively raise bowel cancer risk, reporting their findings in the journal PNAS About 4% of bowel cancer cases are caused by mutations in individual genes, such as the APC gene
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
But scientists believe an additional 20% of cases are caused by the combined effect of many genetic mutations, most of which are insignificant alone.
The team, led by Walter Bodmer, hopes that development of a sophisticated blood test based on new knowledge about these mutations could enable doctors to identify and monitor people at high risk of the disease.
Most bowel cancers develop from polyps in the gut, so having multiple polyps puts individuals at higher risk of developing the disease.
Further reading
Pioneering RNA interference library completed
Two charities have produced the world's first cancer-focussed RNA interference library - a collection of 23,742 designer molecules, created to inactivate a total of 7914 human genes
Another step closer to cracking cancer
The origin of a cancer which is common in people with HIV or who have had an organ transplant, Kaposi sarcoma, points way to possible future therapy
Microscopic envelopes deliver drug to tumours
Molecular envelopes could be used to deliver an anticancer drug to tumours with fewer side effects than the drug alone, a report in the British Journal of Cancer reveals this week
The team compared blood samples from 124 patients who had multiple polyps in their gut with samples from 483 members of the general population.
They found a range of genetic variants in the group with multiple polyps, each twice as frequent on average as in the control group.
Each of these variants appears to increase the likelihood that individuals will develop polyps.
Walter Bodmer, who conducted the research for Cancer Research UK, says: "Patients who had the genetic variants we studied were twice as likely to have multiple polyps in their gut than those who did not.
"Further work will identify additional similar key variant genes that raise a person's risk of bowel cancer.
"I believe we could eventually exploit this knowledge to develop a blood test to identify those at high risk of the disease".
Doctors could actively monitor such patients for cancerous changes in their polyps, and remove them before they develop into bowel cancer.
Further research using samples from a larger number of patients is now planned to confirm associations between particular genetic mutations and multiple polyps.
This work will also lead to the discovery of other mutations responsible for inherited susceptibility to bowel cancer.
Bodmer adds: "Cancer susceptibility is most probably due to the cumulative effect of many individually infrequent genetic variants, rather than a modest effect of one or more common variants.
"This could help explain why it has been difficult to identify specific genes that confer genetic susceptibility to cancer, and also to conditions as varied as schizophrenia and Alzheimer's disease".
Lesley Walker, director of cancer information at Cancer Research UK, says: "Introduction of a national screening programme for bowel cancer was announced last week.
"People over 60 will from April 2006 be screened using a test known as the faecal occult blood test (FOBT) followed by colonoscopy to detect early cancers and polyps.
"However, scientists will continue investigating a range of screening techniques in order to save as many lives as possible.
"Finding the genetic mutations that cause around 20 per cent of bowel cancers will be an important advance in our understanding of the disease, and could also help in efforts to prevent the disease in those at high risk.".
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
